Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies [0.03%]
老年肿瘤患者接受I期临床试验新药的毒副反应和抗肿瘤活性
Geriletu Ao,Maria de Miguel,Ana Gomes et al.
Geriletu Ao et al.
Introduction The number of cancer cases among the elderly continue to increase as the worldwide population ages. This patient subset is underrepresented in clinical trials, partly because of unresolved uncertainties about age-associated tol...
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors [0.03%]
IMC-001（PD-L1阻断剂）治疗转移性或局部晚期实体瘤Ⅰ期临床研究
Bhumsuk Keam,Chan-Young Ock,Tae Min Kim et al.
Bhumsuk Keam et al.
Introduction IMC-001 is a fully human IgG1 monoclonal antibody that binds to human PD-L1 (programmed death-ligand 1). This study evaluated the safety, pharmacokinetics, and pharmacodynamics of IMC-001 in patients with advanced solid tumors....
A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib [0.03%]
日本新药审批制度的批判性评估——以FLT3-ITD抑制剂Qiazartinib为例
Keisuke Kidoguch,Motoharu Shibusawa,Tetsuya Tanimoto
Keisuke Kidoguch
In the last two decades, simultaneous global development of novel drugs become more common by conducting multiregional clinical trials. However, regulatory authorities of different regions often make different decisions on the approvals of ...
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer [0.03%]
LY3076226（一种成纤维细胞生长因子受体3抗体-药物偶联物）Ⅰ期临床研究：在晚期或转移性肿瘤患者中的应用
Christian Kollmannsberger,Carolyn D Britten,Anthony J Olszanski et al.
Christian Kollmannsberger et al.
Background We report a Phase 1 study of LY3076226, an antibody-drug conjugate composed of human IgG1 monoclonal antibody against the human FGFR3 attached with a cleavable linker to the maytansine derivative DM4 in patients with advanced or ...
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis [0.03%]
对于出现脑膜转移的表皮生长因子受体突变非小细胞肺癌患者的再挑战治疗方案的研究
Taichi Miyawaki,Hirotsugu Kenmotsu,Michitoshi Yabe et al.
Taichi Miyawaki et al.
Objectives In EGFR-mutated non-small cell lung cancer (NSCLC) patients, approximately 80-90% of leptomeningeal metastasis (LM) develops after failed initial treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (E...
The biological function of IGF2BPs and their role in tumorigenesis [0.03%]
IGF2BP蛋白的生物学功能及其在肿瘤发生中的作用
Qiu-Ying Du,Zhi-Man Zhu,Dong-Sheng Pei
Qiu-Ying Du
The insulin-like growth factor-2 mRNA-binding proteins (IGF2BPs) pertain to a highly conservative RNA-binding family that works as a post-transcriptional fine-tuner for target transcripts. Emerging evidence suggests that IGF2BPs regulate RN...
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors [0.03%]
一项关于seribantumab（MM-121，抗 HER3 单克隆抗体）用于治疗晚期实体瘤的 I 期剂量递增研究
Crystal S Denlinger,Vicki L Keedy,Victor Moyo et al.
Crystal S Denlinger et al.
Background Overactivation of human epidermal growth factor receptor 3 (HER3) triggers multiple intracellular pathways resulting in tumor cell survival. This Phase 1 study assessed the safety, efficacy, and pharmacokinetics (PK) of seribantu...
Serine hydroxymethyltransferase 2: a novel target for human cancer therapy [0.03%]
丝氨酸羟甲基转移酶2：人类癌症治疗的新靶点
Min Xie,Dong-Sheng Pei
Min Xie
Serine and glycine are the primary sources of one-carbon units that are vital for cell proliferation. Their abnormal metabolism is known to be associated with cancer progression. As the key enzyme of serine metabolism, Serine Hydroxymethylt...
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases [0.03%]
雷莫卢单抗联合厄洛替尼或奥希替尼治疗无症状脑转移的表皮生长因子受体突变阳性晚期非小细胞肺癌患者的Ⅰb期临床研究
Hiroyasu Kaneda,Kenji Sawa,Haruko Daga et al.
Hiroyasu Kaneda et al.
Objectives: The study was designed to investigate the safety of ramucirumab administered in combination with erlotinib or osimertinib for patients with untreated EGFR-mutated non-small cell lung cancer (NSCLC) and asympto...
Network pharmacology of triptolide in cancer cells: implications for transcription factor binding [0.03%]
网络药理学在癌细胞中三氧化二鳞的作用：转录因子结合的启示
Ean-Jeong Seo,Mona Dawood,Annika K Hult et al.
Ean-Jeong Seo et al.
Background Triptolide is an active natural product, which inhibits cell proliferation, induces cell apoptosis, suppresses tumor metastasis and improves the effect of other therapeutic treatments in several cancer cell lines by affecting mul...